GlaxoSmithKline PLC (GSK): Price and Financial Metrics
GET POWR RATINGS... FREE!
GSK POWR Grades
- Value is the dimension where GSK ranks best; there it ranks ahead of 99.19% of US stocks.
- The strongest trend for GSK is in Growth, which has been heading down over the past 179 days.
- GSK ranks lowest in Momentum; there it ranks in the 17th percentile.
GSK Stock Summary
- GSK has a higher market value than 96.73% of US stocks; more precisely, its current market capitalization is $63,270,435,000.
- GSK's went public 36.19 years ago, making it older than 92.82% of listed US stocks we're tracking.
- With a year-over-year growth in debt of -24.73%, GSK PLC's debt growth rate surpasses merely 13.61% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to GSK PLC are STLA, TEL, CMI, DOW, and CTVA.
- GSK's SEC filings can be seen here. And to visit GSK PLC's official web site, go to www.gsk.com.
GSK Stock Price Chart Interactive Chart >
GSK Price/Volume Stats
| Current price | $31.15 | 52-week high | $46.97 |
| Prev. close | $31.49 | 52-week low | $30.83 |
| Day low | $30.83 | Volume | 1,781,529 |
| Day high | $31.15 | Avg. volume | 5,699,065 |
| 50-day MA | $38.51 | Dividend yield | 4.86% |
| 200-day MA | $42.33 | Market Cap | 63.35B |
GlaxoSmithKline PLC (GSK) Company Bio
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The companys wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.
Latest GSK News From Around the Web
Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.
UPDATE 2-Texas judge deems Obamacare HIV prevention drug mandate unlawfulA requirement under the U.S. law known as Obamacare that private insurance plans cover drugs that prevent HIV infection at no cost to patients violates both federal law and the Constitution, a federal judge ruled on Wednesday, siding with conservative lawyers who had challenged the measure on religious grounds. Ruling in Fort Worth, Texas, U.S. District Judge Reed O'Connor found that the HIV pre-exposure prophylaxis, or PrEP, mandate stemmed from a recommendation by an advisory body formed in violation of constitutional requirements and could infringe upon the rights of employers under a law called the Religious Freedom Restoration Act. The mandate is part of the Affordable Care Act (ACA), as Obamacare is formally called. |
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSKSpringWorks Therapeutics Inc (NASDAQ: SWTX) has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (NYSE: GSK) for SpringWorks' nirogacestat with GSK's Blenrep. SpringWorks will receive a $75 million equity investment from GSK, and it is eligible to receive up to $550 million in milestone payments. In May, SpringWorks announced positive topline results from the DeFi Phase 3 trial evaluating nirogacestat in adult patients with progressing desmoid tumor |
GSK's NDA for Daprodustat to be Reviewed by an FDA PanelGSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies. |
SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma- SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments - - SpringWorks to Supply Nirogacestat for GSK’s Global Blenrep Development Program and to Make Nirogacestat Commercially Available in Markets Where a Combination with Blenrep is Approved - - SpringWorks to Continue Retaining Full Global Commercial Rights to Nirogacestat - STAMFORD, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a cl |
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: ReportThe European Union's drugs regulator is just a few weeks away from deciding whether to approve Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) partnered COVID-19 vaccine, Reuters reported, citing Thomas Triomphe, Sanofi's executive vice-president for vaccines. The companies' bivalent vaccine targets the Beta variant as well as the original Wuhan strain of the virus. Trial results also showed that the shot confers protection against the Omicron variant. Sanofi and GSK hope to join the race for va |
GSK Price Returns
| 1-mo | -21.31% |
| 3-mo | -28.09% |
| 6-mo | -21.59% |
| 1-year | -19.45% |
| 3-year | -12.80% |
| 5-year | 0.35% |
| YTD | -26.88% |
| 2021 | 26.64% |
| 2020 | -17.79% |
| 2019 | 29.12% |
| 2018 | 13.70% |
| 2017 | -3.03% |
GSK Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching GSK
Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...